Harriet L. Lancaster , Anna N.H. Walstra , Kyle Myers , Ricardo S. Avila , Jan Willem C. Gratama , Marjolein A. Heuvelmans , Sean B. Fain , David A. Clunie , Ella A. Kazerooni , Maryellen L. Giger , Anthony P. Reeves , Jens Vogel-Claussen , Harry de Koning , Rowena Yip , Luis M. Seijo , John K. Field , James L. Mulshine , Mario Silva , David F. Yankelevitz , Claudia I. Henschke , Matthijs Oudkerk
{"title":"Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer","authors":"Harriet L. Lancaster , Anna N.H. Walstra , Kyle Myers , Ricardo S. Avila , Jan Willem C. Gratama , Marjolein A. Heuvelmans , Sean B. Fain , David A. Clunie , Ella A. Kazerooni , Maryellen L. Giger , Anthony P. Reeves , Jens Vogel-Claussen , Harry de Koning , Rowena Yip , Luis M. Seijo , John K. Field , James L. Mulshine , Mario Silva , David F. Yankelevitz , Claudia I. Henschke , Matthijs Oudkerk","doi":"10.1016/j.ejca.2025.115323","DOIUrl":null,"url":null,"abstract":"<div><div>Reduction in lung cancer mortality is achievable through low dose computed tomography (LDCT) screening in high-risk individuals. Many countries are progressing from local LDCT screening studies to national screening programs. Implementation of effective large-scale screening programs is complex and requires a multi-disciplinary approach. A recent overview of the technical aspects of implementing high quality LDCT for screening resulted from the inaugural international expert meeting of the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE). This covers the most important aspects of the CT imaging process: standardisation in CT image acquisition and interpretation, CT protocol management, technology developments and minimal requirements, integration of lung cancer biomarkers, and the role of AI in CT lung nodule detection, segmentation, and classification, and related data security issues.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115323"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001042","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Reduction in lung cancer mortality is achievable through low dose computed tomography (LDCT) screening in high-risk individuals. Many countries are progressing from local LDCT screening studies to national screening programs. Implementation of effective large-scale screening programs is complex and requires a multi-disciplinary approach. A recent overview of the technical aspects of implementing high quality LDCT for screening resulted from the inaugural international expert meeting of the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE). This covers the most important aspects of the CT imaging process: standardisation in CT image acquisition and interpretation, CT protocol management, technology developments and minimal requirements, integration of lung cancer biomarkers, and the role of AI in CT lung nodule detection, segmentation, and classification, and related data security issues.
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.